Inside Clinica No 1054
This article was originally published in Clinica
Executive Summary
Globalisation of the industry has its share of proponents and detractors, but no area is immune from its effects, especially the more mature markets of the world. Even the largely self-contained Japanese market is belatedly having to open its eyes and react to the effects on its home market of the sharp international business growth ethics that have long been the staple diet of the western world. The government is telling local medical device companies to get more competitive: to shape up or be shipped out from their own domestic market. A rude awakening for the local industry, at a time when its healthcare funding and regulatory sectors are on the threshold of major overhaul (pp 11-13).